ライフサイエンスコーパス: anticardiolipin antibody

1 fetal loss in a mouse pregnancy model due to anticardiolipin antibodies.

2 ding; and those who had detectable levels of anticardiolipin antibodies.

3 Recently, anticardiolipin antibodies (ACA) have been linked with c

4 e (APAS) is characterized by the presence of anticardiolipin antibodies (ACA) in association with thr

5 Antiphospholipid antibodies, including anticardiolipin antibodies (ACA), are strongly associate

6 trongly that lupus anticoagulants (LACs) and anticardiolipin antibodies (ACAs) are antibodies to prot

7 lls treated with a range of human monoclonal anticardiolipin antibodies (aCL) (as anti-beta2-glycopro

8 Yet, standard anticardiolipin antibodies (aCL) immunoassays routinely

9 anti-beta2-glycoprotein I (anti-beta2GPI) or anticardiolipin antibodies (aCL) may be implicated in th

10 Mice infused with IgG containing human anticardiolipin antibodies (aCL) were treated with IVIG

11 Anti-MDA-LDL, anticardiolipin antibodies (aCL), and anti-beta2-glycopr

12 A, C, B/B', and D, for anti-U1 RNA, and for anticardiolipin antibodies (aCL).

13 had lupus anticoagulant and/or high titer of anticardiolipin antibodies (aCL).

14 , thrombin, APC, and plasmin, as well as for anticardiolipin antibody (aCL) activity.

15 rotein AI to OxCL-coated wells increased the anticardiolipin antibody (aCL) binding from APS sera tha

16 uble-stranded DNA (anti-dsDNA) antibody, and anticardiolipin antibody (aCL), as well as proteinuria a

17 La, anti-RNP, lupus anticoagulant (LAC), and anticardiolipin antibody [aCL]) were selected for cluste

18 d lupus anticoagulant (LA) or high titers of anticardiolipin antibodies (ACLAs), either immunoglobuli

19 Anticardiolipin antibodies and anti-beta2GPI were presen

20 otein(a), homocysteine, lupus anticoagulant, anticardiolipin antibodies and genotyping of factor V Le

21 f CL is needed to generate epitopes for many anticardiolipin antibodies and that some of these epitop

22 atients with stroke associated with elevated anticardiolipin antibodies, and we discuss their managem

23 ter IgG or IgM anticardiolipin antibody, IgA anticardiolipin antibody, and anti-beta2-glycoprotein I

24 Anticardiolipin antibodies (antiCl), present in some pat

25 Anticardiolipin antibodies appeared from 7.6 years prior

26 Our findings indicate that anticardiolipin antibodies are frequently elevated in pa

27 iciency, activated protein C resistance, and anticardiolipin antibodies) at predictably greater risk

28 Ls were measured longitudinally: 3 in serum (anticardiolipin antibodies, beta2-glycoprotein I, and an

29 We recently suggested that many anticardiolipin antibodies bind only to oxidized cardiol

30 nd 1 patient each with protein C deficiency, anticardiolipin antibodies, factor VII mutation, factor

31 Anticardiolipin antibodies, found at elevated serum conc

32 uld be proposed in men, aged >40 years, with anticardiolipin antibodies >60 GPLU when TTE is inconclu

33 Positive anticardiolipin antibodies (>22 immunoglobulin G-type ph

34 relationship between dyslipoproteinemia and anticardiolipin antibodies has been demonstrated.

35 and technical complications, but the role of anticardiolipin antibodies has not been evaluated.

36 Lupus anticoagulants and anticardiolipin antibodies have been strongly associated

37 strated that human monoclonal and polyclonal anticardiolipin antibodies have thrombogenic properties

38 aris, thrombocytopenia, low-titer IgG or IgM anticardiolipin antibody, IgA anticardiolipin antibody,

39 nt with acute Q fever and high levels of IgG anticardiolipin antibodies (IgG aCL).

40 ted the possible association between HAT and anticardiolipin antibodies in adult patients who underwe

41 Other potential consequences of anticardiolipin antibodies in end-stage liver disease re

42 Anticardiolipin antibodies in SLE patients tend to prece

43 luded if they had moderate or high levels of anticardiolipin antibodies, lupus anticoagulant, or a hi

44 of Raynaud's phenomenon, as well as elevated anticardiolipin antibodies, lupus anticoagulant, or a hi

45 e not generalizable to women with high-titer anticardiolipin antibodies, lupus anticoagulant, or prev

46 Antiphospholipid antibodies including anticardiolipin antibodies, lupus anticoagulants, and an

47 ity for lupus anticoagulant (P < 0.0001) and anticardiolipin antibodies of the IgG (P = 0.035) or the

48 and the presence of the lupus anticoagulant, anticardiolipin antibodies, or anti-beta(2)-glycoprotein

49 in lymphocyte count or serum immunoglobulin, anticardiolipin antibody, or rubella IgG antibody concen

50 of 35 (63%) liver recipients had a positive anticardiolipin antibody test (either IgG or IgM titer >

51 include measurements of lupus anticoagulant, anticardiolipin antibodies, thyroid function, and a tran

52 either the lupus anticoagulant titer or the anticardiolipin antibody titer on two occasions, separat

53 Determination of IgM and IgG anticardiolipin antibodies was performed by enzyme-linke

54 ng anticoagulant therapy in patients with an anticardiolipin antibody was 1.53 (95% CI, 0.76-3.11), a

55 coagulable state associated with circulating anticardiolipin antibodies, which prompted discontinuati